CRISPR Archives

Biotech By Megan Molteni

In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

Exclusive By Megan Molteni

New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR

First Opinion By Lee D. Cooper

Rediscovering a language of healing that doesn’t require ‘cure’

Biotech By Megan Molteni

3 burning questions spurred by the big CRISPR patent ruling

Biotech By Matthew Herper and Megan Molteni

Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research

In the Lab By Megan Molteni

New CRISPR tools could fix diseases caused by large DNA rearrangements, scientists report

Biotech By Adam Feuerstein

Editas CRISPR treatment improved vision for one patient, but not others, early data show

Biotech By Matthew Herper and Megan Molteni

Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest

In the Lab By Megan Molteni

A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR

STAT Summit By Megan Molteni

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

The Readout LOUD By Meg Tirrell, Adam Feuerstein and Damian Garde

Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

Biotech By Megan Molteni

In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy

Biotech By Adam Feuerstein

CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments

Biotech By Megan Molteni

Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation

First Opinion By Patrick Skerrett

Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more

First Opinion Podcast By Patrick Skerrett

Listen: Walter Isaacson on CRISPR rivals and a Covid truce

First Opinion By Walter Isaacson

CRISPR rivals put patents aside to help in fight against Covid-19

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation

First Opinion By Chris Bakerlee

Mother Nature is not ‘the ultimate bioterrorist’

Biotech By Adam Feuerstein

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

In the Lab By Associated Press

Lab tests show risks of using CRISPR gene editing on embryos

Biotech By Adam Feuerstein

CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy

First Opinion By Patrick Skerrett

Most Read

UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies

Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment

With new trial data coming, Intellia CEO talks up the future of in vivo gene editing

Virtual Event: CRISPR Quest

Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street

Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay

Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0

3 CRISPR editing innovations to watch in 2022

All Coverage

In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR

Rediscovering a language of healing that doesn’t require ‘cure’

3 burning questions spurred by the big CRISPR patent ruling

Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research

New CRISPR tools could fix diseases caused by large DNA rearrangements, scientists report

Editas CRISPR treatment improved vision for one patient, but not others, early data show

Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest

A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails

Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy

CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments

Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation

Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more

Listen: Walter Isaacson on CRISPR rivals and a Covid truce

CRISPR rivals put patents aside to help in fight against Covid-19

Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation

Mother Nature is not ‘the ultimate bioterrorist’

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

Lab tests show risks of using CRISPR gene editing on embryos

CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy

The CRISPR Nobel was about more than two women scientists. It was about all of them

Subscribe to STAT for $15 per month lorem ipsum